Ikarian Capital, LLC Insmed Inc Transaction History

Ikarian Capital, LLC

  • $247 Million
  • Q2 2024

A detailed history of Ikarian Capital, LLC transactions in Insmed Inc stock. As of the latest transaction made, Ikarian Capital, LLC holds 5,070 shares of INSM stock, worth $367,473. This represents 0.14% of its overall portfolio holdings.

Number of Shares
5,070
Previous 51,335 90.12%
Holding current value
$367,473
Previous $1.39 Million 75.65%
% of portfolio
0.14%
Previous 0.18%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$22.0 - $69.71 $77,000 - $243,984
-3,500 Reduced 6.82%
47,835 $3.2 Million
Q1 2024

May 15, 2024
BUY
$25.72 - $29.94 $1.32 Million - $1.54 Million
51,335 New
51,335 $1.39 Million
Q3 2023

Nov 14, 2023
SELL
$19.86 - $26.93 $6.56 Million - $8.89 Million
-330,100 Reduced 68.06%
154,900 $3.91 Million
Q1 2023

May 15, 2023
BUY
$16.26 - $21.73 $7.89 Million - $10.5 Million
485,000 New
485,000 $8.27 Million
Q2 2022

Aug 12, 2022
BUY
$17.07 - $25.71 $2.13 Million - $3.21 Million
125,000 New
125,000 $2.47 Million
Q3 2020

Nov 16, 2020
SELL
$26.0 - $34.5 $75,894 - $100,705
-2,919 Closed
0 $0
Q2 2020

Aug 14, 2020
SELL
$14.11 - $29.42 $2.4 Million - $5 Million
-170,000 Reduced 98.31%
2,919 $80,000
Q1 2020

May 15, 2020
BUY
$13.63 - $33.98 $2.36 Million - $5.88 Million
172,919 New
172,919 $2.77 Million

Others Institutions Holding INSM

# of Institutions
447
Shares Held
170M
Call Options Held
5.79M
Put Options Held
5.18M
View Full List

About INSMED Inc

INSM Quotes by TradingView
  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.82B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email